New York Magazine examines cancer drug pricing

Share this article:
New York Magazine examines cancer drug pricing
New York Magazine examines cancer drug pricing

In a story published online on October 20th, New York magazine took readers through the Memorial Sloan-Kettering/Zaltrap pricing battle with Leonard Saltz, one of the three oncologists who penned the op-ed in the New York Times which started it all and concluded with Sanofi/Regeneron slashing the price of then new breast cancer drug Zaltrap in half due to "market resistance."

The seven-page article online also quoted Hagop Kantarjian, head of the Department of Leukemia at the University of Texas's MD Anderson Cancer Center, who is currently campaigning against Gleevec, a leukemia treatment whose price has tripled since 2001.

Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.